Specific complement inhibition with heparin-coated extracorporeal circuits

Annals of Thoracic Surgery

Volumn 61, Issue 4, 1996, Pages 1153-1157

  Te Velthuis, Henk ^a   Jansen, Piet G M ^b   Hack, C Erik ^b   Eijsman, León ^b   Wildevuur, Charles R H ^b  

^a CENTRAL LABORATORY   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; HEPARIN;

AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; EXTRACORPOREAL CIRCULATION; FEMALE; HUMAN; INSTRUMENTATION; INTRAOPERATIVE PERIOD; INTRAVENOUS ANESTHESIA; MALE; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

AGED; ANESTHESIA, INTRAVENOUS; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; CORONARY ARTERY BYPASS; EXTRACORPOREAL CIRCULATION; FEMALE; HEPARIN; HUMANS; INTRAOPERATIVE PERIOD; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 0030118055     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(95)01199-4     Document Type: Article

References (25)

1. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-57.
2. Balzo UHD, Levi R, Polley MJ. Cardiac dysfunction caused by human C3a anaphylatoxin. Proc Natl Acad Sci USA 1985;82: 886-90.
3. Hammerschmidt DE, Harnes PE, Wayland JH, Craddock PR, Jacob HS. Complement induced granulocyte aggregation in vivo. Am J Pathol 1981;102:146-50.
4. Salama A, Hugo F, Heinrich D, et al. Deposition of the terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med 1988;318:408-14.
5. Chenoweth DE, Cooper SW, Hugli TE, Steward RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass. Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-502.
6. Van Oeveren W, Kazatchkine MD, Descamps-Latscha B, et al. Deleterious effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1988;22:251-6.
7. Mollnes TE, Videm V, Götze O, Harboe M, Oppermann M. Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin. Ann Thorac Surg 1991;52: 92-7.
8. Cavarocchi NC, Schaff HV, Orszulak TA, Homburger HA, Schnell WA, Pluth JR. Evidence for complement activation by heparin-protamine interaction after cardiopulmonary bypass. Surgery 1985;98:525-31.
9. Weiler JM, Yurt RW, Fearon DT, Austen FK. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med 1978;147:409-21.
10. Kazatchkine MD, Fearon DT, Silbert JE, Austen KF. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particlebound C3b. J Exp Med 1979;150:1202-15.
11. Maillet F, Kazatchkine MD, Glotz D, Fisher E, Rowe M. Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. Mol Immunol 1983;20:1401-4.
12. Rent R, Myhrman R, Fiedel BA, Gewurz H. Potentiation of C1-esterase inhibitor activity by heparin. Clin Exp Immunol 1976;23:264-71.
13. Videm V, Mollnes TE, Garred P, Svennevig JL. Biocompatibility of extracorporeal circulation. J Thorac Cardiovasc Surg 1991;101:654-60.
14. Gu YJ, van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevuur CRH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917-22.
15. Videm V, Svennevig JL, Fosse E, Semb G, Osterlund A, Mollnes TE. Reduced complement activation with heparin-coated oxygenators and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992;103:806-13.
16. Fosse E, Moen O, Johnson E, et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472-7.
17. Pekna M, Borowiec J, Fagerhol MK, Venge P, Thelin S. Biocompatibility of heparin-coated circuits used during cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1994; 28:5-11.
18. Jansen PGM, te Velthuis H, Huybregts RAJM, et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 1995;110:829-34.
19. Hack CE, Paardekooper JA, van Milligen F. Demonstration in human plasma of a form of C3 that has the conformation of "C3b-like C3." J Immunol 1990;144:4249-55.
20. Hack CE, Paardekooper J, Eerenberg AJM, et al. A modified competitive inhibition radioimmunoassay for the detection of C3a. Use of 125I-C3 instead of 125I-C3a. J Immunol Methods 1988;108:77-84.
21. Hack CE, Paardekooper J, Smeenk RJT, Abbink J, Eerenberg AJM, Nuijens JH. Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3. An analysis with monoclonal antibodies. J Immunol 1988;141:1602-9.
22. Wolbink GJ, Bollen J, Baars JW, et al. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993;163: 67-76.
23. Pekna M, Nilsson L, Nilsson-Ekdahl K, Nilsson UR, Nilsson B. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin Exp Immunol 1993;91:404-9.
24. Nilsson-Ekdahl K, Nilsson B, Pekna M, Nilsson UR. Generation of iC3 at the interface between blood and gas. Scand J Immunol 1992;35:85-91.
25. Boackle RJ, Caugham GB, Vesely J, Medgyesli G, Fudenberg HH. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway. Mol Immunol 1983;20:1157-64.